Response of Pediatric Choroidal Neovascularization to Anti-Vascular Endothelial Growth Factor

por Ruparelia, Sunil, Sundaram, Aishwarya, Dahrab, Mishari, Symonds, Chris, Cruess, Alan
Publicado 2021

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

por Kaiser, Peter K., Cruess, Alan F., Bogaert, Peter, Khunti, Kamlesh, Kelly, Simon P.
Publicado 2012

Erratum to: Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

por Kaiser, Peter K., Cruess, Alan F., Bogaert, Peter, Khunti, Kamlesh, Kelly, Simon P.
Publicado 2013

Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment

por Ziemssen, Focke, Cruess, Alan, Dunger-Baldauf, Cornelia, Margaron, Philippe, Snow, Howard, Strain, William David
Publicado 2017